Home › NCT07096453
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
RecruitingPhase 1/2
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients: a PK Pilot Study
Who can join
Ages 18 to 70 · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult (18-70 year old) kidney transplant recipients * Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion * CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor * EBV IgG Positive Exclusion Criteria: * Pregnant people * Subjects unwilling to sign consent and complete follow up visits * Subjects with IgA immunodeficiency * Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment * Patients who do not speak English and would need a translator and translated consent materials in order to obtain informed consent
About the study
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
What is being tested
- Cytogam (drug)
Sponsor: University of Minnesota · Participants: 30 · Started: Oct 2, 2025
Contact the study team
- Elise Reed · Phone: 612-624-9695
Official record on ClinicalTrials.gov — NCT07096453
Locations in the U.S.
| Minnesota | University of Minnesota, Minneapolis |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.